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Purpose: A major limitation of performing hemiablative focal therapy (FT) for prostate cancer (PCa) is the possibility of accompanying 
significant cancer in the contralateral side of the prostate that is missed on prostate biopsy. We attempted to verify whether clinical 
and biopsy-related parameters can be used to predict the absence of significant cancer in the prostate lobe.
Methods: We assumed that hemiablative FT could be performed in patients with low-risk PCa, with unilateral tumors as assessed 
by transrectal ultrasound-guided biopsy. We evaluated 214 patients who had undergone radical prostatectomy (RP) and fulfilled the 
eligibility criteria. Seemingly preserved lobes, defined by the absence of cancer on biopsy, were classified as lobes with no cancer (LNC), 
lobes with insignificant cancer (LIC), and lobes with significant cancer (LSC) according to RP pathology. Cases with an estimated tumor 
volume of <0.5 mL, a Gleason score of <7, and organ confinement without Gleason pattern 4 were classified as LIC. Univariate and 
multivariate logistic regression analyses were performed to identify predictors for LSC. Predictive accuracies of the multivariate models 
were assessed using receiver operating characteristic curve-derived areas under the curve. 
Results: Of 214 evaluated lobes, 45 (21.0%), 62, (29.0%), and 107 (50.0%) were classified as LNC, LIC, and LSC, respectively. Among the 
clinical and biopsy-related parameters, prostate-specific antigen density and prostate volume were identified as significant predictors 
for LSC in univariate regression analysis. However, multivariate analysis did not identify an independent predictor. Predictive accuracies 
of the multivariate models did not exceed 70.4%.
Conclusions: Conventional parameters have limited value in predicting LSC in patients who are candidates for hemiablative FT.
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INTRODUCTION
In the era of prostate-specific antigen (PSA) measurement, 
prostate cancer (PCa) is increasingly being detected at an 
early stage and with a low risk, but the management of local-
ized PCa remains controversial because early detection and 
conventional treatment do not seem to be able to reduce 
mortality and improve the quality of life [1,2]. Radical whole 
gland surgery or radiation therapy can result in substantial 
side effects. Urinary incontinence (5%–20%), erectile dys-
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function (30%–50%), and bowel toxicity (5%–10%) are typical 
complications of radical treatment [3,4]. For the treatment of 
low-risk PCa, active surveillance (AS) can be a treatment op-
tion; however cancer-related anxiety is the major drawback to 
this course [5].
 Focal therapy (FT) is receiving increasing attention as a 
middle ground between AS and radical treatment, to selec-
tively eradicate localized PCa while preserving uninvolved 
structures to minimize treatment-related side effects [6-8]. 
Hemiablative FT, which involves ablation of the entire half of 
the prostate associated with cancer, might be the most feasible 
and straightforward form of FT [9]. Hemiablative FT can be 
used even in cases of bilateral PCa with a significant unilateral 
lesion and an insignificant lesion on the contralateral side. 
This is because the index lesion determines the clinical out-
come, and the secondary lesions are unlikely to result in dis-
ease progression [10,11]. Some authors claim that FT targeting 
an index lesion alone may be sufficient when supplemented 
with AS for the untreated insignificant lesions [7,12,13]. 
 For the performance of appropriate hemiablative FT, the 
side contralateral to the ablated lobe is supposed to contain 
no significant lesions. We attempted to identify conventional 
prostate biopsy and clinical characteristics that could predict 
the presence of significant cancer in the seemingly preserved 
lobe, contralateral to the lobe with the index lesion.
MATERIALS AND METHODS
Between January 2008 and October 2012, 1,140 men un-
derwent RP for PCa at Seoul National University Bundang 
Hospital, Seongnam, Korea. Clinical data for these men had 
previously been entered into a prospectively maintained 
computerized database. After obtaining Institutional Review 
Board approval, we reviewed the data on 832 of these patients 
who had undergone prostate biopsy using a single technique 
at our institution. After the measurement of prostate volume, 
all patients underwent transrectal ultrasound (TRUS)-guided 
12-core biopsy of the prostate. The prostate was biopsied at 
both sides near the base, midgland, and apex, with at least six 
biopsy specimens obtained per side. In cases of lesions suspi-
cious for PCa based on TRUS, one or two additional targeted 
biopsy specimens were obtained. Low-risk patients (clinical 
stage ≤ T2a; Gleason score [GS] ≤ 6; and PSA level < 10 ng/mL) 
with a unilateral tumor as proven by TRUS biopsy were se-
lected as candidates for hemiablative FT. Of the 832 patients 
who underwent RP using a single technique, 310 had low-risk 
PCa, and of these 310 patients, 214 had unilateral tumors as 
proven by biopsy.
 All biopsy and RP specimens were analyzed by a single 
genitourinary pathologist (G.C.), and RP specimens were pro-
cessed according to the Stanford Protocol [14]. Tumor volume 
was measured by multiplying the X and Y diameters and tu-
mor depth, which was calculated according to the thicknesses 
of subsequent sections that showed the presence of tumor, 
as previously described and validated [15,16]. We classified 
the preserved lobes as lobes with no cancer (LNC), lobes with 
insignificant cancer (LIC), and lobes with significant cancer 
(LSC) according to the RP pathologic reports. Using the Ep-
stein criteria [17], cases with a total tumor volume accounting 
for all foci of <0.5 mL, a GS of <7, and organ confinement 
without Gleason pattern 4 on one side were classified as LIC. 
If the index tumor was located between both lobes, we con-
sidered it to be present on the preserved side. To evaluate the 
possibility of preserving one lobe of the prostate by perform-
ing hemiablative FT, LNC or LIC was considered suitable for 
hemiablative FT. 
1. Statistical analyses
Categorical variables are presented as frequencies and per-
centages, and continuous variables are presented as mean ±  
standard deviation. Age, PSA level, percentage of positive 
cores among the total biopsy cores (% of positive cores), and 
the maximum percentage of tumor length in positive cores (% 
of tumor length) were entered into the models as continuous 
variables. Clinical T stage, PSA density (PSAD), and GS were 
treated as dichotomous variables. Logistic regression mod-
els were conducted for univariate and multivariate analyses 
to identify significant predictors of LSC. Receiver operating 
characteristic (ROC) curve-derived areas under the curve 
(AUCs) were calculated for each parameter in the multivari-
ate model for estimating LSC. All statistical analyses were 
performed using IBM SPSS ver. 20.0 (IBM Co., Armonk, NY, 
USA). A two-tailed P-value of < 0.05 was considered signifi-
cant for all analyses.
RESULTS
The clinical and biopsy-related characteristics of patients 
are shown in Table 1. The mean patient age was 65.14 ± 6.82 
years. cT1b, cT1c, and cT2a disease were identified in 1 (0.5%), 
174 (81.3%), and 39 patients (18.2%), respectively. The mean 
PSA level was 5.56 ± 1.20 ng/mL, and the PSAD was 0.16 ± 0.08 
ng · mL-1 · cm-3. The mean prostate volume was 38.36 ± 13.84 
cm3. Further, 159 (74.3%), 32 (15.0%), and 22 patients (10.3%) 
underwent 12-, 13-, and 14-core biopsy, respectively, and 
126 patients (58.9%) showed only one positive core on TRUS-
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guided biopsy. The percentage of positive cores was 14.34% ± 
10.01%. The maximum core and tumor lengths were 16.80 ± 
7.16 and 2.90 ± 2.35 mm, respectively, and the percentage of 
tumor length was 17.95% ± 14.93%.
 Of the 214 preserved lobes, 45 (21.0%) were found to have 
no cancer and cancer was detected in the RP specimens of 
the other 169 lobes. The GS was ≤ 3+3 in 87 lobes (40.7%) and 
≥ 3+4 in 82 lobes (38.8%). Nine lobes (4.2%) showed extra-
prostatic extension, and 67 lobes (31.3%) had a tumor volume 
of ≥ 0.5 cm3. Accordingly, 45 (21.0%), 73 (34.1%), and 96 lobes 
(44.9%) were classified as LNC, LIC, and LSC, respectively 
(Table 2).
 We examined the associations between clinical and biop-
sy-related variables and the lobe category. Of the clinical and 
biopsy-related parameters, GS was excluded from regression 
analysis because all patients showed a GS of 6 except for 1 
who had GS of 5 based on the analysis of TRUS-guided biopsy 
specimens. Univariate logistic regression analysis showed 
that PSAD and prostate volume were significant predictors of 
LSC, but multivariate analysis did not identify any parameter 
as an independent predictor (Table 3).
 To estimate the predictive accuracy of each parameter for 
LSC, ROC curve-derived AUCs were calculated. AUCs for all 
parameters were less than 64%, the largest being for PSAD, 
at 63.9%. The predictive accuracy of a multivariate model, in-
cluding age, PSAD, prostate volume, and the other variables 
mentioned here, for predicting LSC was 70.4% (Table 3). The 
predictive accuracies of other multivariate models incorpo-
rating age and PSAD with various combinations of the other 
variables were < 70%.
DISCUSSION
Recent studies including ours showed that 17%–22% of men 
undergoing RP have PCa confined to one side of the gland, 
although the populations in these studies were different 
[9,18,19]. In our cohort of 214 patients with low-risk PCa, 
107 (55.1%) did not have significant cancer in the seemingly 
preserved side. Thus, a substantial proportion of men with 
Table 1. Clinical and biopsy-related characteristics of the pa-
tients
Characteristic Value
Age (yr) 65.14±6.82
Body mass index (kg/m2) 24.35±2.56
Clinical state
≤T1c 175 (81.8)
T2a 39 (18.2)
PSA level (ng/mL) 5.56±1.20
PSAD (ng · ml-1 · cm-3) 0.16±0.08
Prostate volume (cm3) 38.36±13.84
Gleason score
5 1 (0.5)
6 213 (99.5)
% of positive core 14.34±10.01
% of tumor length 17.95±14.93
Values are presented as mean±standard deviation or number (%).
PSA, prostate-specific antigen; PSAD, PSA density.
Table 2. Pathologic features of preserved lobes as assessed on 
the basis of the radical prostatectomy permanent report
Variable Preserved prostate lobes
Gleason score
≤3+3 87 (40.7)
≥3+4 82 (38.3)
Extraprostatic extension 9 (4.2)
Tumor volume≥0.5 cm3 67 (31.3)
Lobe category
LNC 45 (21.0)
LIC 73 (34.1)
LSC 96 (44.9)
Values are presented number (%).
LNC, lobe with no cancer; LIC, lobe with insignificant cancer; LSC, lobe 
with significant cancer.
Table 3. Univariate and multivariate logistic regression analysis for the prediction of lobes with significant cancer
Variable
Univariate Multivariate
OR (95% CI) P-value AUC (%) OR (95% CI) P-value AUC (%)
Age 1.03 (0.99–1.07) 0.19 54.3 1.04 (1.00–1.09) 0.06
Body mass index 0.91 (0.82–1.01) 0.08 57.2 0.95 (0.84–1.07) 0.38
Clinical stage (T2a vs. ≤T1c) 0.48 (0.23–1.01) 0.05 54.8 0.48 (0.22–1.04) 0.06
PSA 1.09 (0.95–1.25) 0.21 56.1 1.07 (0.86–1.34) 0.55
PSAD (≥0.15 vs. <0.15) 3.13 (1.79–5.48) <0.01 63.9 1.95 (0.74–5.11) 0.18
Prostate volume 0.97 (0.95–0.99) 0.03 63.2 0.97 (0.94–1.01) 0.13
% of positive core 1.01 (0.98–1.04) 0.43 53.6 1.01 (0.98–1.04) 0.63
% of tumor length 1.00 (0.98–1.02) 0.98 52.4 0.99 (0.97–1.02) 0.56
Total 70.4
PSA, prostate-specific antigen; PSAD, PSA density; AUC, area under the curve; OR, odds ratio; CI, confidence interval.
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clinically low-risk PCa can be treated with hemiablative FT. 
Here, we attempted to identify the clinical and biopsy-related 
parameters that could predict the presence of pathologically 
significant cancer in the lobe contralateral to the side treated 
with ablation. However, no independent predictors were iden-
tified in multivariate regression analysis. In addition, none of 
the parameters or multivariate models showed satisfactory 
predictive accuracies in ROC curve-derived AUC analysis.
 Previous studies reported that PSA, taking more prostate 
biopsy cores, maximum cancer length and familiy history of 
PCa were predictor factor of tumor unilaterality based upon 
RP [9,18-20]. As for the prediction of pathologically insignifi-
cant or unfavourable PCa among low-grade PCa cancers, 
some reported that PSAD and age were correlated with insig-
nificant PCa [21,22]. On the other hand, other authors failed to 
identify clinical or biopsy-related parameters predicting such 
pathological outcome [23,24]. There are still controversies to 
find predictor factor of tumor laterality and clinical significan-
cy in PCa patients with preoperative parameters. The differ-
ences of experimental group, biopsy protocol and pathologic 
reporting system were thought of main causes of those results.
 Prebiopsy magnetic resonance imaging (MRI) has the 
benefit of facilitating prior detection of lesions not expected 
to be identified by systematic prostate biopsy. However, in 
a large study, Giannarini et al. [25] showed that differentia-
tion between PCa and normal prostatic tissue, not only in the 
transition zone but also in the peripheral zone, is very difficult 
based on T2-weighed images. The conventional approach to 
managing cases with a high PSA level is TRUS-guided prostate 
biopsy followed by MRI for PCa staging. Conditions other than 
PCa such as postbiopsy hemorrhaging, scaring, positional and 
inflammatory changes, and dystrophic changes can interfere 
with the accuracy of MRI investigations [26,27]. Therefore, we 
did not include MRI parameters in our evaluations for identi-
fying predictive factors and estimating predictive accuracies.
 Matsuoka et al. [28] reported that a combination of diffu-
sion-weighted imaging and extended prostate biopsy can 
efficiently be used to predict lobes without significant cancer. 
In their study, the negative predictive value for predicting LSC 
was 95.7%. However, indolent cancer was defined as organ-
confined disease with a tumor volume of < 0.5 cm3 and a GS 
of ≤ 3+4 without Gleason pattern 5. Although definitions of 
significant cancer vary, a GS of 3+4 seems too high to accept 
as representative of insignificant cancer. FT represents a po-
tential compromise between AS and radical therapy, offering 
advantages of the resolution of anxiety and the avoidance of 
urinary and sexual side effects associated with whole gland 
treatment [9]. The management strategy must not only meet 
the curative intent of treatment, but must also account for the 
safety of AS. Thus, strict criteria may be required in determin-
ing the clinical significance of the preserved side based on 
pathologic reports of RP specimens.
 The current study has several limitations. First, we did not 
include all patients with low-risk PCa detected at our institu-
tion. Those treated with AS or radiation therapy were exclud-
ed from this study, because we were unable to obtain final 
pathologic reports for them. Application of FT is not limited 
to patients who are due to receive RP, and so our study may 
contain a selection bias associated with the inclusion criteria. 
In addition, in a hypothetical study based on a database of RP 
patients, we attempted to determine appropriate selection 
criteria for FT. However, this therapy was not administered to 
patients with PCa, and so we were unable to assess biochemi-
cal recurrence and cancer-specific survival, which might be 
more important than pathological features for selection of FT.
 In conclusion, among patients with low-risk PCa who had 
unilateral tumors based on conventional multicore ( ≥ 12) 
biopsy, 44.9% had pathologically determined LSC and 34.1% 
harbored LIC. However, no independent predictors of LSC in 
patients who are candidates for hemiablative FT were identi-
fied. In addition, our data showed that the clinical and biop-
sy-related parameters currently available have limited value 
in the prediction of pathologically determined LSC. Further 
efforts should be made to identify more accurate predictors 
of actual pathological characteristics and prognosis of PCa to 
ultimately improve the selection of candidates for hemiabla-
tive FT.
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